Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

$ARVN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ARVN alert in real time by email

NEW HAVEN, Conn., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 2:30 p.m. ET in New York.

A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company's website.

About Arvinas

Arvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts

Investors:

Jeff Boyle

+1 (347) 247-5089

Jeff.Boyle@arvinas.com

Media:

Kirsten Owens

+1 (203) 584-0307

Kirsten.Owens@arvinas.com



Primary Logo

Get the next $ARVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Q&A

New
  • What type of company is Arvinas, Inc.?

    Arvinas, Inc. is a clinical-stage biotechnology company focused on creating drugs based on targeted protein degradation.

  • Who represents Arvinas, Inc. at the Piper Sandler 36th Annual Healthcare Conference?

    Noah Berkowitz, M.D., Ph.D., Chief Medical Officer and Andrew Saik, Chief Financial Officer.

  • When will Arvinas, Inc. participate in the Piper Sandler Healthcare Conference?

    The presentation will take place on Tuesday, December 3 at 2:30 p.m. ET.

  • What investigational drugs is Arvinas currently developing?

    Arvinas is working on multiple investigational drugs, including vepdegestrant, ARV-393, and ARV-102, targeting conditions like breast cancer and neurodegenerative disorders.

  • Will the presentation at the Piper Sandler Conference be accessible to the public?

    A live audio webcast of the presentation will be available on the company's website and via the provided link in the announcement.

Recent Analyst Ratings for
$ARVN

DatePrice TargetRatingAnalyst
12/10/2024$69.00Buy
BTIG Research
11/18/2024$55.00Overweight
Stephens
2/28/2024$95.00 → $80.00Outperform
Oppenheimer
2/14/2024$36.00 → $55.00Buy → Neutral
Citigroup
2/1/2024$70.00Buy
Goldman
12/19/2023$25.00 → $63.00Equal Weight → Overweight
Wells Fargo
12/6/2023$40.00Hold → Buy
Jefferies
11/20/2023Neutral → Buy
Guggenheim
More analyst ratings

$ARVN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology compan

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

    – Vepdegestrant to be combined with Pfizer's novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will combine vepdegestrant with a CDK4/6 inhibitor, also planned to initiate in 2025 – – Topline data from the monotherapy Phase 3 VERITAC-2 trial of vepdegestrant anticipated in 1Q25 – – The Company recently initiated a Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson's disease – – Data disclosures anticipated from multiple clinical and pre-clinical programs, including ARV-102 and ARV-393, and planned IND submission for a PROTAC KRAS G12D degrader in 2025 – NEW HAVEN, C

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ARVN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ARVN
SEC Filings

See more

$ARVN
Leadership Updates

Live Leadership Updates

See more
  • Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm

    $ARVN
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

    Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

    $ARVN
    $GMDA
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

    - Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Andrew Saik to the role of Chief Financial Officer and Treasurer reporting to Chairperson, Chief Executive Officer, and President, John Houston, Ph.D. "It is a pleasure to welcome Andrew as our new Chief Financial Officer," said John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas. "Andrew is a seasoned executive in biopharma finance with extensive

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Financials

Live finance-specific insights

See more
  • Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Announced the planned initiation of first-line Phase 3 trial evaluating vepdegestrant in combination with Pfizer's novel investigational CDK4 inhibitor atirmociclib and a second-line Phase 3 combination trial evaluating vepdegestrant with a CDK4/6 inhibitor, both planned to begin in 2025 – –

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

    NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology compan

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    – On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a

    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ARVN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more